ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PGEN / news
XERS (64) MRVI (37) ZBIO (38) TRAX (44) ⌘ Pro Terminal →

Why PGEN Stock dropped -25.94% Today — RQD Quant Desk Flash

$5.14 -25.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.89

Precigen Inc. (PGEN) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.84B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PGEN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Precigen Inc. (NASDAQ: PGEN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $5.14 (-25.94% 1D, market cap $1.84B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PGEN ranks #667 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PGEN compare to XERS and MRVI in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PGEN carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XERS (Xeris Biopharma Holdings Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.85B) and MRVI (Maravai LifeSciences Holdings Inc. (Class A)) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.87B). Among the 5-stock peer group, PGEN leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PGEN?
▼

Per PGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001356090), Precigen Inc. generated $9.7M in revenue (+146.7% YoY), -$250.6M in net income, and -$89.8M in free cash flow against $155.5M in total assets and $93.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.89 (-4.86%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk E
Cash (8)Whales (11)SEC (6)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.3% Base Target
$9 Bull$5 Base$4 Bear
📬 FREE PGEN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PGEN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY PGEN SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$7.36-10.3% Next Q
Q2 (-2Q)
38
Grade E$6.60-7.9% Next Q
Q3 (-1Q)
36
Grade E$6.08-15.5% Next Q
Current
33
Grade E$5.14-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PGEN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PGEN currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.16) and Max Pain ($5.40) forces dealer call-delta covering toward $9.43.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PGEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PGEN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why PGEN Stock dropped -25.94% Today — RQD Quant Desk Flash

Precigen Inc. (PGEN) dropped -25.94% to $5.14, trading at 35% of its 52-week range ($3.04 – $8.98). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 35% of its 52-week range ($3.04 – $8.98) with RSI-14 at 32.6 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.14 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live PGEN Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PGEN)

  • ✓Walkthrough of PGEN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.71%▼ SUPPORT BREAKDOWN
2026-11-04O $6.94H $6.94L $5.14C $5.14VOL 20.62M
RES: $10.06SUP: $6.43SMA50: $7.16SMA200: $5.30
$9.36$7.78$6.19$4.60$3.02RES $10.06SUP $6.43$5.142026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PGEN Butterfly Map → + Track PGEN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +146.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PGEN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PGEN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PGEN)

Health Care Rank #667 of 1015 ⚔️ XERS vs PGEN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PGEN vs. XERS, MRVI, ZBIO, TRAX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Precigen Inc. (PGEN) ranks #667 by composite RQD confidence (33/100, grade E) and #266 by equity capitalization ($1.84B). Within this direct 5-issuer industry benchmark cohort, PGEN leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with PGEN at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PGEN ACTIVE
Precigen Inc.
E 33/100 — — -35.0% -25.94% $1.84B Benchmark Subject
XERS
Xeris Biopharma Holdings Inc.
C 64/100 — — 16.0% -5.04% $1.85B /xers-vs-pgen →
MRVI
Maravai LifeSciences Holdings Inc. (Class A)
D- 37/100 — 18.3% -35.0% -7.94% $1.87B /mrvi-vs-pgen →
ZBIO
Zenas BioPharma Inc.
D- 38/100 — — -35.0% -2.71% $1.80B /zbio-vs-pgen →
TRAX
First Tracks Biotherapeutics Inc.
D 44/100 — — -35.0% -0.07% $1.89B /trax-vs-pgen →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001356090 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Precigen Inc. (PGEN) reported GAAP revenue of $9.7M (+146.7% vs. FY2024 revenue of $3.9M , and +55.6% cumulative change since FY2023) , GAAP net income of -$250.6M, operating cash flow of -$87.8M, and free cash flow of -$89.8M (-17.0% YoY). On the balance sheet, PGEN closed FY2025 with $155.5M in total assets against $93.2M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $9.7M -$250.6M -$87.8M -$89.8M $155.5M $93.2M
FY2024 (FY) 2024-12-31 $3.9M -$126.2M -$68.2M -$76.8M $145.3M $0
FY2023 (FY) 2023-12-31 $6.2M -$95.9M -$66.9M -$66.9M — —

3. PGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Precigen Inc. (NASDAQ: PGEN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $5.14 (-25.94% 1D, market cap $1.84B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PGEN ranks #667 in composite RQD confidence.

How does PGEN compare to XERS and MRVI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PGEN carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XERS (Xeris Biopharma Holdings Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.85B) and MRVI (Maravai LifeSciences Holdings Inc. (Class A)) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.87B). Among the 5-stock peer group, PGEN leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PGEN?

Per PGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001356090), Precigen Inc. generated $9.7M in revenue (+146.7% YoY), -$250.6M in net income, and -$89.8M in free cash flow against $155.5M in total assets and $93.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PGEN trading relative to its 50-day, 200-day, and 52-week technical levels?

PGEN last traded at $5.14 (-25.94% on volume of 20,620,730 shares), positioning the stock -28.21% below its 50-day simple moving average ($7.16) and -3.02% below its 200-day simple moving average ($5.30). Across its 52-week range of $3.04 to $8.98, PGEN sits at the 35.4% percentile with a 14-day RSI of 32.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.50 to $5.78).

Direct Sub-Reports: PGEN RQD Cockpit PGEN 12M Forecast PGEN Earnings & Move PGEN Dividends & DRIP PGEN Insiders & 13F PGEN Whale Options PGEN Profit Sankey PGEN News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

PGEN — Precigen Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Precigen Inc. (PGEN) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $5.14 (-25.94% 1D, market capitalization $1.84B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -3.78%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (6/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of 4.46x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Precigen Inc. (PGEN) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It has a market capitalization of $2.4B. Reported revenue was $9.7M for FY 2025, indicating a small revenue base relative to its operating losses.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Precigen Inc. (PGEN) reported $9.7M in annual revenue (up from $3.9M in FY2024, +146.7% YoY) and -$250.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.2M revenue, -$95.9M net income) through FY2025, PGEN scaled operating cash flow to -$87.8M and free cash flow to -$89.8M, backed by $155.5M in total assets against $93.2M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.78% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $3.04 – $8.98 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlation links are therefore — The 2nd-order ripples a prospective investor should monitor cannot be mapped from the provided sources; the only sector context available is the Health Care / Biotechnology classification.

  • Key Question #1: Can PGEN sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $9.7M and free cash flow of -$89.8M, how will capital allocation balance growth reinvestment against $93.2M in total debt?
  • Key Question #3: How sensitive is PGEN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PGEN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Precigen Inc. (PGEN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PGEN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PGEN Bull vs. Bear Conversation Board — What's Your Call at $5.14?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PGEN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PGEN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $8.81 (+26.9%)
📌 Pinned Debate

Institutional accumulation and options positioning (10/20 Whale 13F pillar) plus a +9.21% price move and 52-week low of $3.04 show stro

Institutional accumulation and options positioning (10/20 Whale 13F pillar) plus a +9.21% price move and 52-week low of $3.04 show strong recent market momentum.. When you look under the hood at PGEN, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (11/20) has been quietly accumulating below $8.98. My 12M target is $8.81.

SectorRotator 🐂 BULL

@SiliconVal_Bull Agree on the RQD 33/100 quality, though with 1.0 beta I'm scaling in with half-size at $6.94 and keeping dry powder in case we test $6.45.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $5.55 (-20.0%)
Spot @ $6.94

Negative ROIC of -35%, FCF yield of -3.78%, and Debt/Equity of 4.46 leave the stock with weak cash generation and elevated forensic bal

Negative ROIC of -35%, FCF yield of -3.78%, and Debt/Equity of 4.46 leave the stock with weak cash generation and elevated forensic balance sheet risk.. Look at the math on PGEN: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $6.11 before getting long.

LIVE TAPE